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Abstract: Characterization of the genes expressed in adipose tissue (AT) is key to 
understanding the pathogenesis of obesity and to developing treatments for this condition. 
Our objective was to compare the gene expression in visceral AT (VAT) between obese 
and normal-weight prepubertal children. A total of fifteen obese and sixteen normal-weight 
children undergoing abdominal elective surgery were selected. RNA was extracted from 
VAT biopsies. Microarray experiments were independently performed for each sample  
(six obese and five normal-weight samples). Validation by quantitative PCR (qPCR) was 
performed on an additional 10 obese and 10 normal-weight VAT samples. Of 1276 
differentially expressed genes (p < 0.05), 245 were more than two-fold higher in obese 
children than in normal-weight children. As validated by qPCR, expression was 
upregulated in genes involved in lipid and amino acid metabolism (CES1, NPRR3 and 
BHMT2), oxidative stress and extracellular matrix regulation (TNMD and NQO1), 
adipogenesis (CRYAB and AFF1) and inflammation (ANXA1); by contrast, only CALCRL 
gene expression was confirmed to be downregulated. In conclusion, this study in 
prepubertal children demonstrates the up- and down-regulation of genes that encode 
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molecules that were previously proposed to influence the pathogenesis of adulthood 
obesity, as well as previously unreported dysregulated genes that may be candidate genes 
in the aetiology of obesity. 
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1. Introduction 
Childhood obesity is one of the most important public health problems of the 21st century, affecting 
both developed and developing countries. Early-onset obesity is associated with an increased incidence 
of adult obesity, type 2 diabetes, non-alcoholic fatty liver disease and cardiovascular risks factors [1]. 
Obesity is characterized by an increased body mass index (BMI) as a consequence of weight gain, 
which may be implicated in the remodelling of adipose tissue (AT) [2]. Currently, it is known that AT 
acts as an endocrine organ that is capable of secreting hormones, cytokines, growth factors and 
vasoactive substances, among other factors, which are involved in regulating body weight, glucose 
homeostasis, lipid metabolism angiogenesis, reproduction and immunity [3,4]. AT can be divided into 
specific depots; subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) are two major 
types of AT in adult humans, and they have distinct characteristics [5]. Metabolic disorders are more 
strongly associated with VAT, which is possibly because secretions from this tissue may reach the 
liver and because the gene expression profile and the biochemical and metabolic properties of VAT 
may also contribute to the preferential association of VAT with metabolic dysfunction in obese 
subjects [6]. Differences in gene expression between SAT and VAT have previously been reported  
in adults. VAT is associated with insulin resistance, diabetes, hypertension, atherosclerosis, and 
hepatic steatosis, whereas SAT responds better to insulin and secretes more adiponectin and smaller 
amounts of inflammatory cytokines [7]. Moreover, VAT from patients with extreme obesity expresses 
more genes than SAT or epigastric AT, suggesting a more specialized lineage and specific functional 
properties of this depot [8].  
Therefore, studying the genome-wide mRNA expression profile of VAT might be a useful tool for 
analysing the mechanisms of weight regulation and understanding the development of obesity and its 
comorbidities. Most microarray-based expression studies that have been published to date have been 
performed on obese adults and have compared the gene expression profiles in VAT vs. SAT [8–10]. 
Only two have examined the different expression profiles in the VAT of obese adults and normal-weight 
adults [11,12]. Regarding studies performed in children, only one has compared the gene expression 
data for SAT and VAT [13]. Studies in prepubertal children can offer important insight into the genetic 
basis of obesity because excess weight during the growing years constitutes a major risk for being 
overweight or obese during adult life. Furthermore, prepubertal children are not affected by the 
hormonal changes associated with puberty, which affect body fat distribution [14]. 
Overall, our primary objective was to determine the gene expression profile of fat depots in obese 
and normal-weight prepubertal children. To the best of our knowledge, this study is the first to analyse 
whole genome expression in VAT from prepubertal obese children and to compare it with that in 
normal-weight children. The present study was performed to clarify the effect of obesity on the gene 
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expression profile of VAT in prepubertal children, by using DNA microarrays and subsequently to 
validate these findings with quantitative PCR (qPCR) methods. 
2. Results and Discussion 
2.1. Anthropometric and Biochemical Characteristics of the Study Population 
The clinical characteristics of the 11 children selected for the microarray analysis and those of the 
20 additional children included in the qPCR analysis are shown in Table 1. 
Table 1. Clinical and biochemical characteristics of the prepubertal children. 
 Microarray qPCR 
Characteristics Normal-Weight (n = 6) Obese (n = 5) Normal-Weight (n = 10) Obese (n = 10) 
Sex (M:F) 5:1 5:0 6:4 8:2 
Age (years) 8.2 ± 0.6 10.2 ± 0.6 9.3 ± 0.8 9.5 ± 0.5 
Weight (kg) 28.8 ± 1.1 55.8 ± 2.9 * 32.9 ± 2.7 50.9 ± 3.6 * 
Height (m) 131.4 ± 3.4 141.0 ± 4.0 136.2 ± 4.2 138.9 ± 4.3 
BMI (kg/m2) 16.8 ± 0.6 28.1 ± 0.7 * 17.5 ± 0.5 26.1 ± 0.7 * 
BMI z score −0.61 ± 0.36 3.12 ± 0.5 * −0.6 ± 0.2 2.8 ± 0.3 * 
Systolic BP (mm·Hg) 111.3 ± 3.20 123.0 ± 7.1 109.1 ± 2.6 119.9 ± 4.5 
Diastolic BP (mm·Hg) 61.3 ± 3.0 71.2 ± 5.6 60.3 ± 3.2 67.8 ± 3.9 
Glucose (mmol/L) 4.73 ± 0.30 4.95 ± 0.19 4.9 ± 0.2 5.1 ± 0.3 
Insulin (pmol/L) 9.0 ± 1.6 19.3 ± 7.2 10.4 ± 1.6 11.1 ± 1.4 
HOMA-IR 1.8 ± 0.32 4.3 ± 1.7 2.3 ± 0.33 2.4 ± 0.31 
TAG (mmol/L) 0.77 ± 0.19 0.67 ± 0.09 0.88 ± 0.18 0.80 ± 0.09 
TC (mmol/L)  4.19 ± 3.44 4.21 ± 0.57 3.86 ± 0.25 4.22 ± 0.42 
HDL-C (mmol/L) 1.54 ± 0.09 1.78 ± 0.23 1.42 ± 0.15 1.40 ± 0.11 
LDL-C (mmol/L) 2.29 ± 0.26 2.11 ± 0.43 2.02 ± 0.21 2.44 ± 0.34 
Apo A-1 (g/L) 0.12 ± 0.08 1.44 ± 0.05 1.23 ± 0.10 1.19 ± 0.09 
Apo B (g/L) 0.74 ± 0.09 0.61 ± 0.10 0.67 ± 0.07 0.73 ± 0.09 
Adiponectin (mg/L) 14.8 ± 0.3 5.9 ± 3.6 16.7 ± 1.9 11.8 ± 1.9 
Leptin (μg/L) 27.9 ± 2.3 33.1 ± 4.8 27.3 ± 1.7 34.8 ± 3.4 
CRP (g/L) 0.29 ± 0.09 0.32 ± 0.14 0.29 ± 0.08 0.46 ± 0.09 
M, male; F, female; BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; 
TAG, triacylglycerols; TC, total cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; Apo, 
apolipoprotein; and CRP, C-reactive protein. The data are shown as the means ± SEM. Differences between the 
normal-weight and obese groups were analysed with the non-parametric Mann-Whitney U test. * p < 0.05. 
There were no significant differences in the age or height between obese and control children; 
however, the weight and BMI were significantly higher in the obese subjects included in both the array 
and qPCR analyses. No significant differences were found in the blood pressure, fasting glucose, 
insulin, triacylglycerol (TAG), total cholesterol, insulin resistance (calculated by the homeostatic 
model assessment, HOMA-IR) or lipoprotein-related parameters. The fasting plasma adiponectin 
concentrations tended to be lower in the obese children than in the normal-weight children in both analyses. 
Conversely, the leptin plasma level tended to be higher in the obese vs. normal-weight children. The  
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C-reactive protein plasma concentrations were similar between the obese and normal-weight selected 
children for the microarray analysis and for the qPCR confirmation. 
There were no significant differences in the carbohydrate and lipid metabolism parameters of 
normal-weight and obese children, which could be because of the small number of samples. In fact, we 
described higher systolic and diastolic BP, as well as higher plasma TAG, insulin and HOMA-IR and 
lower HDL-C levels in a bigger population of study of obese children [15,16]. 
2.2. Gene Expression Profile of Visceral Adipose Tissue in Obese Children 
The gene expression profile of VAT tissue from six control and five obese children was obtained 
using the Human Genome HG-U133 Plus 2.0 array from Affymetrix. After filtering data with the 
Affymetrix Detection Algorithm, out of 12,057 filtered sequences, 11,097 were expressed in obese and 
10,595 in normal-weight children. The majority of genes were expressed in both conditions; 960 genes 
were exclusively expressed in tissues from normal-weight children and 1462 in obese adipose  
(Figure 1). Of the 12,057 filtered sequences, 1588 were differentially expressed between obese 
children and normal-weight children (p < 0.05), as determined by GeneSpring software. Hierarchical 
clustering analysis of these genes allowed the samples to be adequately separated by experimental 
condition (obese or normal-weight) (Figure 2). 
Out of the 1588 probe sets, 1276 corresponded to single annotated genes because more than one 
probe set detected a similar change for the same gene in some cases, providing additional validation of 
the expression data. Out of these 1276 genes, 245 were expressed at a more than two-fold higher level 
in AT from obese children than in AT from normal-weight children, including 201 that were up-regulated 
(82%) (Table S1) and 44 that were down-regulated (18.1%) (Table S2). The 245 differentially 
expressed genes were classified according to the biological process in which they are involved, 
following the criteria of the Gene Ontology (GO) Consortium. The genes belong to a diverse range of 
biological processes, including metabolism, cell signalling and cell adhesion, and extracellular matrix 
development (Tables S1 and S2). 
 
Figure 1. Venn diagram of the expressed sequences in the visceral adipose tissue of  
obese and normal-weight prepubertal children. After filtering the data with the Affymetrix 
Detection Algorithm, a total of 12,057 sequences were found to be expressed in adipose 
tissue. Each condition is represented by a circle in the Venn diagram. The numbers in the 
region of the overlapping circles indicate the genes that are expressed in both conditions. 
 
















Figure 2. Microarray analysis of the transcripts expressed in the visceral adipose tissue 
from obese vs. normal-weight (control) prepubertal children. RNA from each patient was 
subjected to chip analysis using Affymetrix Human Genome U133Plus 2.0 GeneChips. 
The normal-weight group consists of six individuals (numbers 1–6), and the obese group 
consists of five patients (numbers 7–11). Bidimensional cluster analysis was performed 
using a Pearson correlation. The parametric test ANOVA was used to uncover the 1588 
genes that were differentially expressed. 
Additionally, differentially expressed transcripts were subjected to Ingenuity Pathway Analysis. 
“Lipid Metabolism, Small Molecule Biochemistry, Endocrine System, Development and Function” was 
the top score network identified. Twenty-two of 26 genes involved in the network were upregulated 
and four were down-regulated (Figure S1). Regarding the canonical pathway, four of them were 
positive z-score: Gαi Signalling (p = 0.0011) with seven molecules of 118 (0.059) (ADRA2A↑, 
GNAI1↑, GNG11↑, NPR3*↑, P2RY14↑, RGS4↑, SHC1↑), cAMP-mediated signalling (p = 0.0012) with 
7 molecules of 213 (0.033) (ADRA2A↑, ADRB2↑, AKAP12↑, GNAI1↑, NPR3*↑, P2RY14↑, RGS4↓), 
ILK signalling (p = 0.0365) with six molecules of 181 (0.033) (ARHGEF6↑, CCND1↑, IRS2↑, ITGB5↑, 
JUN↑, RHOB↑), and IL-8 Signalling (p = 0.0382) with six molecules of 183 (0.033) (CCND1↑, GNAI1↑, 
GNG11↑, ITGB5↑, JUN↑, RHOB↑). No pathway was found to have a negative z-score. 
This study is the first to shows a distinct gene expression pattern in VAT from obese and normal-weight 
prepubertal children. As in adults [11,12], the majority of the differentially expressed genes encoded 
proteins that are mainly involved in metabolism, cell signalling, immune responses, the extracellular 
matrix and signal transduction. Moreover, our results also revealed the up-regulation of genes involved 
in cell death (regulation of apoptosis and regulation of programmed cell death) and cell proliferation 
regulation, but down-regulation of the genes involved in induction of apoptosis and induction of 
programmed cell death were also observed. Furthermore, we have found that 2.6% of 245 
differentially expressed genes contribute to regulating the inflammatory response. There are higher 
percentages of the differentially expressed genes in VAT than in SAT in prepubertal children [13] and 
adults [8], and the presence of inflammation and an immune response were the leading altered 
pathways in both studies. The observed discrepancy in the percentages might be explained by studies 
assessing differences in the gene expression between subcutaneous and visceral fat.  
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Among the differentially expressed genes that were previously found in VAT from obese and 
normal-weight adults [11,12], we have replicated and validated by qPCR the down-regulation of the 
expression of the CALCRL (calcitonin receptor-like) gene reported by Baranova et al. [12] with  
a similar fold change (FC) value of approximately 2.5. Surprisingly, the results published by  
Gomez-Ambrosi et al. [11] describe genes that are differentially expressed in the opposite directions of 
our findings. The CDKN1C (Cyclin-dependent kinase inhibitor 1C), NPR3 (natriuretic peptide 
receptor C) and ADRB2 (adrenergic beta-2-receptor surface) genes were found to be down-regulated 
with FC values of 2.5, 3.2 and 2.2, respectively, which is in contrast to the up-regulation found in the 
present study. None of those three genes was validated by qPCR in the study performed in adults. By 
contrast, we found similar up-regulation of FC values for NPR3 expression (4.31 and 5.1 by array and 
qPCR, respectively). This finding reinforces that validation of microarray data are required, as we 
discuss below. 
2.3. Validation of Gene Expression Data by qPCR 
To more precisely quantify the differential expression found by microarray analysis, a total of  
73 genes (54 up- and 19 down-regulated) out of the total 245 differentially expressed genes, were 
selected for validation by qPCR. The criteria for gene selection were based on the degree of 
differential expression of each gene and its known functional roles in metabolic disease. qPCR assays 
were performed in 20 additional VAT samples (10 obese and 10 normal-weight samples). Table S3 
depicts a comparison of the microarray and qPCR results. The differential gene expression data  
were only confirmed for 11 genes (20% of the total selected genes) (Table 2). All of these were  
up-regulated, except for CALCRL, which was down-regulated. Among the up-regulated genes,  
we validated the expression of leptin (LEP), one of the best-known genes, whose expression is altered 
in obesity, confirming the obesity-induced changes in mRNA expression. In accordance with the 
literature [17], we found elevated up-regulation of LEP mRNA expression in the VAT of obese 
children compared with lean subjects. 
Table 2. Genes with altered expression, confirmed by qPCR, in the AT of obese 
prepubertal children compared to normal-weight children. 
Symbol Name 
Microarrays qPCR 
Fold Change p Value Fold Change * p Value 
CES1 carboxylesterase 1  11.74 0.001 3.0 0.050 
TNMD tenomodulin protein 7.19 0.028 5.5 0.028 
LEP leptin (obesity homolog, mouse) 4.44 0.005 3.5 0.050 
NPR3 natriuretic peptide receptor C 4.31 0.005 5.1 0.006 
NQO1 NAD(P)H dehydrogenase, quinone 1 3.99 0.006 2.8 0.041 
BHMT2 betaine-homocysteine methyltransferase 2 3.14 0.005 2.3 0.049 
CRYAB crystallin, alpha B 2.25 0.005 2.6 0.034 
AFF1 AF4/FMR2 family, member 1 2.20 0.004 2.9 0.041 
ANXA1 annexin A1 2.14 0.037 1.9 0.049 
ITGB5 integrin, beta 5 2.12 0.000 1.3 0.050 
CALCRL calcitonin receptor-like -2.64 0.006 -2.4 0.034 
* ΔCt values were compared between obese and normal-weight children using the non-parametric Wilcoxon test (p < 0.05). 
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Interestingly, the expression (as delta Ct) of several genes were correlated with some clinical and 
biochemical parameters (Table S4). Delta Ct represents the difference between the Ct value of a gene 
and that of the control gene (GUS). In other words, a higher delta Ct means a lower gene expression 
and conversely a lower delta Ct means a higher gene expression. It is interesting to note that delta Ct 
values of ANXA1 (r = −0.55, p = 0.01), NPR3 (r = −0.54, p = 0.02) and CALCRL (r = −0.47, p = 0.04) 
were negatively associated with serum leptin levels. It is noteworthy that TNMD (r = −0.49, p = 0.03), 
NPR3 (r = −0.56, p = 0.01), and AFF1 (r = −0.47, p = 0.05) were the only genes associated with BMI, 
but TNMD (r = −0.51, p = 0.02), NPR3 (r = −0.48, p = 0.04) and NQO1 (r = −0.45, p = 0.05) expression 
were associated with BMI z score. Similarly, NPR-3 (r = −0.61, p = 0.01) and AFF1 (r = −0.47, p = 0.04) 
were correlated with weight. Interestingly, delta Ct values of CES1, TNMD, LEP, NPR3, NQO1, 
BHMT2 and ITGB5 were negatively associated with systolic blood pressure. Meanwhile ANXA1 were 
positively associated with serum HDL-C levels. 
Microarray technology is a powerful tool for screening the gene expression profiles of biological 
samples, but it is mandatory to validate the obtained results with a highly reliable biotechnique that 
allows the precise quantification of the transcriptional abundance of the identified genes. qPCR is 
accepted as an appropriate method for gene expression array data validation. However, it is important 
to note that the study design followed by researchers widely differs at each stage of the validation 
process: (a) Gene selection is not always performed based on the degree of differential expression. 
Selection bias in genes, based on a pathway of interest, is frequent in genome-wide transcription 
analysis; (b) Separate samples should be used to perform an independent qPCR validation, whereas 
some studies use the same samples that were used in the array experiment. Considering these issues, 
we cannot compare and discuss the rate of validation of our study with those in previous studies. 
Therefore, the discussion focuses on the genes whose expression, as determined by microarray, was 
validated by qPCR. Although different biological functions have been reported as mediated by  
a number of those genes, we have classified them according to the best-known function.  
2.3.1. Lipid and Amino Acid Metabolism  
A key factor in energy balance is the mobilization of lipids through lipolysis in fat cells, and basal 
lipolysis is higher in obese individuals than non-obese individuals [18]. The main enzymes mediating 
the lipolysis in AT are adipose triglyceride lipase and hormone-sensitive lipase; however, the 
importance of other lipases, such as carboxylesterase 1 (CES1), is unclear and CES1 has been reported 
to play a major role in the trafficking of lipids and lipid metabolism in hepatocytes [19]. We found  
up-regulation of CES1 expression; this gene encodes an enzyme that mediates adipocyte lipolysis 
through the hydrolysis of cholesteryl esters and triglycerides [18]. The expression of CES1 is highly 
regulated in adult AT; there are higher levels in obese subjects and lower levels during a weight loss 
period [20]. In addition, the SAT mRNA levels of CES1 are positively associated with BMI, HOMA, 
fasting glucose, insulin and TAG in adults [21,22]. Our findings in the VAT from children confirm the 
findings in adults, indicating that CES1 may have a role in the development of obesity-associated 
phenotypes. It is not yet known whether this lipase is more important to the TAG metabolism in the 
liver than to AT. 
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In contrast to the increased AT lipolytic activity, we found up-regulation of NPR3, which may have 
an antilipolytic effect through receptor inhibition of lipolysis mediated by natriuretic peptides [23]. 
The results from a large-cohort epidemiological study suggested that in the obese state, insulin might 
suppress the circulating levels of natriuretic peptides via up-regulating NPR-3 expression [24]. 
However, it is noteworthy that the activation of NPR-3 in human thyroid cells increased the cAMP 
levels, which may suggest an alternative role for NPR-3 [25] in AT.  
The plasma concentrations of several amino acids are elevated in obesity and insulin resistance in 
humans, but there is no conclusive evidence about whether these amino acid alterations are causal. In 
the present study, we found, for the first time, up-regulated expression of the betaine-homocysteine 
methyltransferase 2 (BHMT2) gene. BHMT2 catalyses the formation of the amino acid methionine 
from homocysteine using the choline metabolite betaine as a methyl donor. Although this enzyme  
is predominantly found in the liver, deletion of the mouse Bhmt gene reduces adiposity owing to  
an increased whole body metabolic rate, impaired TAG synthesis, and enhanced glucose oxidation  
in white AT [26]. This highlights the relationship between the over-expression of BHMT2 and 
development of obesity.  
2.3.2. Oxidative Stress and Extracellular Matrix Related Genes 
AT function is regulated by the physiological interaction between cells and a variety of extracellular 
proteins [27]. Among them, integrin beta 5 (ITGB5) was up-regulated in our sample of obese children. 
Henegar et al. [28] also showed that ITGB5 and other genes encoding the members of the integrin 
family were significantly induced and co-expressed in SAT from obese adults. Moreover, tenomodulin 
(TNMD), an angiogenesis inhibitor, which may play a role in AT function and has been implicated in 
extracellular matrix remodelling [29,30], was up-regulated in our sample of obese children. This 
finding is in concordance with the results of Saiki et al. [30]. In addition, the TNMD mRNA levels 
strongly correlate with the BMI, insulin sensitivity and leptin levels in adults [29,30].  
Increased oxidative stress, resulting in the generation of reactive oxygen species (ROS), is observed 
in obesity, which might explain the over-expression of NAD(P)H dehydrogenase quinone 1 (NQO1)  
in the present study. NQO1 is highly expressed in human AT, especially in large adipocytes, and  
it correlates with adiposity, glucose tolerance, and liver dysfunction markers in obese adults [31]. 
2.3.3. Adipogenesis Related Genes 
We found up-regulation of CRYAB (crystallin, alpha B), which has been implicated in apoptosis, 
and CRYAB expression, induced during adipogenesis. In agreement with our results, Lehr et al. 
demonstrated that CRYAB expression in the VAT of obese subjects is significantly higher than in that 
of lean controls [32]. In addition, calcitonin receptor-like (CALCRL), a G-protein coupled receptor for 
the adrenomedullin peptide, was found to be down-regulated. Adrenomedullin is present at higher 
levels in both the plasma and AT of obese individuals than in those of lean subjects and is considered 
to be a member of the adipokine family [33]. Adrenomedullin has been described as an antiadipogenic 
factor because the reduction of adrenomedullin synthesis strongly accelerates adipose differentiation [34]. 
The down-regulation of the receptor found in children in the present study, and in adults by  
Baranova et al. [12] could explain the increased levels of adrenomedullin described in obesity. 
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Another adipogenesis-associated gene with up-regulated expression was the AF4/FMR2 family 
member 1 (AFF1). Although a polymorphism in the AFF1 gene has been associated with an increase in 
circulating TAG, its function in lipid metabolism is not known [35]. AFF1 may have a role in 
regulating the cyclin-dependent kinase inhibitor CDKN1B [36] and may therefore be involved in  
cell cycle regulation. Genes of the cyclin-dependent kinase inhibitor family are involved in cell 
proliferation and differentiation within AT [37] and could therefore be involved in the hyperplasia 
mechanisms at the onset of obesity. 
2.3.4. Inflammation-Related Gene 
Validation of the microarray data confirmed the up-regulation of Annexin A1 (ANXA1), a protein 
that mediates the anti-inflammatory action of glucocorticoids. ANXA1 is a member of the annexin 
superfamily of calcium-binding and phospholipid-binding proteins; these results in children are in 
agreement with previous results in obese subjects after weight loss [28]. It is interesting that the plasma 
levels of ANXA1 in humans are inversely correlated with markers of adiposity, although ANXA1 gene and 
protein expression are significantly up-regulated during adipogenesis in a human adipocyte cell line [38]. 
3. Experimental Section  
3.1. Study Population 
We recruited 31 Caucasian children, aged 6–12 years, undergoing abdominal surgery in the 
Pediatric Surgery Unit of the Hospital Reina Sofía (Cordoba, Spain) with a diagnosis of hernia or false 
positive diagnosis of acute appendicitis. Of 31 children, 15 (13 boys and 2 girls) were obese, and  
16 were normal-weight children (11 boys and 5 girls) according to Cole et al. [39]. All children were 
in the prepubertal period based on the Tanner criteria (Tanner I) (Tanner, 1962) and as validated by 
plasma sex hormone concentrations. The inclusion criteria were a good state of health, age between  
5 and 14 years and the absence of endogenous obesity. Exclusion criteria were disease or malnutrition 
and the use of a medication that alters blood pressure or glucose or lipid metabolism.  
The children’s parents or guardians were informed about the purpose and procedures of the  
study before written consent was obtained, and all children agreed to participate. The protocol was 
performed in accordance with the Revised Declaration of Helsinki and following the recommendations 
of the Good Clinical Practice of the European Union (document 111/3976/88 July 1990) and legal  
in-force Spanish regulations, which regulate clinical investigation in human beings (RD 223/04 about 
Clinical Assay), as approved by the Ethics Committees of all participants’ institutions. 
3.2. Anthropometric and Biochemical Measurements 
A single examiner performed all anthropometric measurements according to standardized methods. 
Body weight (kg) and height (cm) were measured using standardized procedures, and BMI was 
calculated as the weight (kg) divided by the square root of the height (m2). Systolic and diastolic  
blood pressures were measured three times at 5-min intervals while children were seated, using  
a standardized mercury sphygmomanometer and adapted cuff size; the final two measurements were 
averaged for the analysis. The pubertal stage was determined in each patient according to Tanner’s 
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criteria and was validated by plasma sex hormone concentrations. Children in Tanner stage I were 
considered prepubertal, and those in Tanner stages II–V were considered pubertal. 
Blood was obtained by venipuncture before surgery and was divided into aliquots for immediate 
analysis or storage at −80 °C until analysis. Glucose was analysed using the glucose oxidase method in 
an automatic analyser (CV 1%) (Roche-Hitachi Modular PyD Autoanalyzer, Roche Laboratory 
Systems, Mannheim, Germany), and plasma insulin was analysed by radioimmunoassay (CV 2.6%) 
(Axsym, Abbott Laboratories, Chicago, IL, USA). The insulin resistance index was calculated with  
the homeostatic assessment model (HOMA-IR). Total adiponectin was determined by RIA (LINCO 
Research Inc) and leptin by ELISA (BioSource International Inc., Camarillo, CA, USA). The plasma 
total, HDL and LDL cholesterol; TAG; apolipoprotein A-1 and –B; and C-reactive protein (CRP) 
levels were analysed using an automatic analyser (Roche-Hitachi Modular P and D Autoanalyzer).  
3.3. Adipose Tissue Biopsy and Total RNA Preparation 
During abdominal surgery, approximately 400 mg of visceral (intra-abdominal) AT was collected 
and excised into pieces of approximately 150 mg, which were each immediately immersed in 1.5 mL 
RNA-later solution (Qiagen, Izasa, Spain) and stored at −80 °C until analysis. Total RNA from VAT 
biopsies was isolated using the RNeasy Lipid Tissue Midi Kit (Qiagen, Izasa, Spain). The integrity of the 
total RNA was checked by visual inspection of the 28S and 18S RNA on agarose gel electrophoresis. 
3.4. Microarray Analysis 
RNA samples from six control and five obese children were used for the microarray analysis. A 
total of 11 chips were used (one per tissue sample). Subsequent RNA processing procedures followed 
the protocols in the GeneChip Expression Analysis Technical Manual (Affymetrix, Santa Clara, CA, 
USA). Briefly, five micrograms of total RNA was used as the starting material for the Affymetrix sample 
preparation. cDNA was synthesized with the SuperScript Choice System Kit (Life Technologies 
Corporation, Izasa, Spain). The cDNA was used for the cRNA synthesis using an IVT Labeling kit 
(Affymetrix, Santa Clara, CA, USA) and then purified using a GeneChip Sample Cleanup Module Kit 
(Affymetrix). Fifteen micrograms of biotin-labelled cRNA was fragmented and hybridized to the  
HG-U133 Plus2.0 array (Affymetrix), which offers comprehensive analysis of the genome-wide 
expression on a single array, analysing the expression level of over 47,200 transcripts corresponding to 
38,500 well-characterized human genes. 
After scanning, the digitized image data were processed using GCOS 1.1 software (Affymetrix), 
and analysed with GeneSpring software (Silicongenetics, Fremont, CA, USA). Significant differences 
between the obese and control genes were tested using a one-way ANOVA. Hierarchical clustering 
analysis was performed with Pearson correlation for sample classification. Differences were considered 
significant at p < 0.05. The results are expressed as the FC of obese vs. control children. 
Among the differentially expressed genes (p < 0.05 and FC ≥ 2 or FC ≤ 2), dataset functional 
analysis was performed using Gene Ontology (GO) terms with the Database for Annotation, 
Visualization and Integrated Discovery (DAVID), available online [40]. Additionally, biological 
networks and canonical pathways were analyzed by QIAGEN’s Ingenuity® Pathway Analysis, 
available online [41], for the 245 genes with an altered expression. Both direct and indirect 
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relationships were considered. The association between the data set and the canonical pathway was 
determined by a P value calculated with the right-tailed Fisher exact test. The complete data sets in the 
present study comply with the MIAME (Minimum Information About a Microarray Experiment) 
requirements, which are available from the National Center for Biotechnology Information Gene 
Expression Omnibus web site [42]; accession no. GSE9624. 
3.5. qPCR Analysis 
To validate the differential gene expression obtained by microarrays, qPCR was performed on  
a panel of 73 selected genes based on their possible implication in the development of obesity and 
microarray differential expression (p < 0.05 and FC ≥ 2 or FC ≤ 2). The validation was performed on 
20 additional VAT samples (10 obese and 10 control samples). Total RNA was obtained as described 
above. After DNase I treatment (Ambion, Paisley, UK), 1 μg of total RNA was reverse transcribed into 
cDNA using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). qPCR 
was performed using a GeneAmp 7900 Sequence Detection System and TaqMan Assays-on-Demand 
Gene Expression Products (Applied Biosystems). The TaqMan Human Endogenous Control Plate 
(Applied Biosystems) was used to select the best candidate as an endogenous control gene (GUS). The 
ΔΔCt method was used to calculate the relative changes in the mRNA abundance as FC values. 
3.6. Statistical Analysis 
Demographic and biochemical data were compared between obese and normal weight children 
using the non-parametric Mann-Whitney U test. 
Statistical analysis of qPCR data was performed by analysing the ΔCt values, which were calculated 
by subtracting the Ct number of each target gene from that of the endogenous control GUS gene. The 
ΔCt values were compared between obese and control children with the non-parametric Wilcoxon test, 
as recommended by Yuan et al. [43]. Spearman correlation coefficient was performed between gene 
expression values, as delta Ct, and clinical and biochemical characteristics. Statistical analysis was 
carried out using the SPSS 22.0 software for Windows (SPSS Inc., Chicago, IL, USA). 
4. Conclusions 
To the best of our knowledge, this study reports the first investigation of prepubertal children in 
which obesity-induced gene expression changes have been globally analysed in VAT using genome 
wide microarrays, providing valuable new insight into the pathology of early-onset human obesity.  
Our data demonstrate that the VAT of obese children exhibits a gene expression profile that differs 
from their normal-weight peers. More genes and a wider spectrum of genes were expressed in the AT 
of obese children, including some genes that have not previously been described. Differential gene 
expression that was validated by qPCR confirmed the up-regulation of genes related to lipid and amino 
acid metabolism (CES1, NPRR3 and BHMT2), oxidative stress and extracellular matrix regulation 
(TNMD and NQO1), adipogenesis (CRYAB and AFF1) and inflammation (ANXA1), while CALCRL 
gene expression was the only gene confirmed to be downregulated.  
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In conclusion, this study in prepubertal children demonstrates that there is a different gene 
expression signature in the VAT of obese pre-pubertal children, some of them previously proposed to 
influence the pathogenesis of adulthood obesity, as well as newly uncovered dysregulated genes that 
may be candidate genes in the aetiology of obesity. Our findings reinforce the current concept that 
obesity is a complex trait and provides new insight into the pathology of early-onset human obesity. 
However, our study has some limitations; we had a relatively low number of subjects, but also we used 
VAT, which is composed of adipocytes, together with other cells, such as macrophages, vascular cells and 
other blood cells. Further studies are needed to clarify the specific role of these genes in childhood obesity. 
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